FRANCE Law and Practice Contributed by: Emmanuelle Trombe, Anthony Paronneau and Anne-France Moreau, McDermott Will & Schulte
McDermott Will & Schulte is ranked among the top life sciences and health law firms and operates from over 20 locations with more than 1,400 lawyers de- livering highly effective solutions across practices and geographies. The global Life Sciences practice group provides critical guidance to leading life sci- ences companies and investors. With 160+ lawyers in the US and Europe, the team advises biotechnol-
ogy, pharmaceutical and medical technology com- panies on complex FDA/regulatory, transactional, intellectual property and litigation matters. The team offers solid experience and creative solutions and the firm represents 75% of the top 20 biopharmaceutical companies globally. A special thanks to Caroline Noyrez, Nejma Palasse and Alice Dartevelle for their invaluable support.
Authors
Emmanuelle Trombe is a partner at McDermott Will & Schulte and
Anne-France Moreau is a partner at McDermott Will & Schulte and has over a decade of experience counselling clients on corporate and general commercial law, with a particular focus on the
co-heads the firm’s Life Sciences industry practice. She represents pharmaceutical, medical device and biopharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio- pharmaceutical companies in connection with a broad range of financing activities. As well as co-heading the firm’s Life Sciences group, Emmanuelle serves as an elected member of the firm’s management committee.
pharmaceutical, medical device, health care and cosmetics industries. Anne-France assists French and non-French groups in the preparation and negotiation of collaborations, licences and distribution agreements. She has experience on a number of merger, acquisition and private equity transactions, including divestitures, financing rounds and joint ventures for French and non-French corporations. Further, Anne-France regularly handles digital health matters as well as regulatory issues.
Anthony Paronneau is a partner at McDermott Will & Schulte and advises clients on all aspects of corporate and business law, with a particular focus on the pharmaceutical, medical device,
biotech and healthcare industries. Anthony has significant experience advising life sciences companies, private equity funds and venture capital firms on a number of M&A and private equity transactions, including acquisitions, financing rounds, joint ventures and divestitures. He also regularly advises life sciences companies on collaborations, licensing and distribution arrangements.
85 CHAMBERS.COM
Powered by FlippingBook